Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Overcoming obstacles: new management options.

L Heinemann1

  • 1Profil Institute for Metabolic Research GmbH, Hellersbergstr. 9, D-41460 Neuss, Germany. Lutz.Heinemann@profil-research.de

European Journal of Endocrinology
|October 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Auto-antibodies against carbonyl-modified vimentin in COPD: potential role as a biomarker.

Journal of inflammation (London, England)·2025
Same author

Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.

Endocrine·2017
Same author

HbA1c and Age in Non-Diabetic Subjects: An Ignored Association?

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2016
Same author

Home Use of an Artificial Beta Cell in Type 1 Diabetes.

The New England journal of medicine·2015
Same author

Biosimilar insulins: guidance for data interpretation by clinicians and users.

Diabetes, obesity & metabolism·2015
Same author

Biosimilar insulins: a European perspective.

Diabetes, obesity & metabolism·2014
Same journal

Correction to: Steroidogenic factor-1 regulates a core set of target genes to promote malignancy in adrenocortical carcinoma.

European journal of endocrinology·2026
Same journal

Improving post-thyroidectomy care using a PTH and calcium-based algorithm.

European journal of endocrinology·2026
Same journal

Sampling variability and concordance between sequential and simultaneous adrenal venous sampling in primary aldosteronism subtype diagnosis.

European journal of endocrinology·2026
Same journal

Independent Clonal Evolution in Primary Pigmented Nodular Adrenocortical Disease: A Single-Patient Multi-Omics Study.

European journal of endocrinology·2026
Same journal

Twenty years of neurosurgical experience with Cushing's disease: surgical-strategies, endocrine outcomes and remission predictors in 346 patients.

European journal of endocrinology·2026
Same journal

Long-term Clinical Outcomes of Primary Adrenal Insufficiency Caused by Homozygous CYP11A1 p.R451W Variant.

European journal of endocrinology·2026
See all related articles

New advancements in type 2 diabetes management, including novel insulin analogues and continuous glucose monitoring, offer improved blood glucose control and patient compliance. These innovations aim to overcome barriers to insulin therapy, enhancing treatment outcomes and reducing long-term complications.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes management faces challenges with existing therapies.
  • Barriers to insulin initiation include injection pain, frequency, and side effect concerns.
  • Current glucose monitoring methods can be invasive and provide limited data.

Purpose of the Study:

  • To review emerging diabetes management options for type 2 diabetes.
  • To highlight advancements improving glycemic control and patient adherence.
  • To discuss how new therapies can mitigate barriers to effective insulin treatment.

Main Methods:

  • Review of current literature on new diabetes management strategies.
  • Analysis of novel insulin analogues and delivery systems.

Related Experiment Videos

  • Evaluation of continuous glucose monitoring technologies.

    • Main Results:

    • New insulin analogues (lispro, aspart, glargine) offer physiological replacement and mealtime flexibility.
    • Non-invasive insulin administration routes are under development.
    • Continuous glucose monitoring promises accurate insulin dosing and reduced need for finger-stick tests.
    • Emerging therapies aim to expand treatment choices and improve patient outcomes.

    Conclusions:

    • Advancements in diabetes care are improving blood glucose control and patient compliance.
    • New tools empower clinicians to create personalized treatment plans.
    • These innovations are expected to reduce the incidence of late-stage diabetes complications.